Assessing the impact of haemodynamic monitoring with CardioMEMS on heart failure patients : a cost-benefit analysis
Codina, Pau (Universitat Autònoma de Barcelona. Departament de Medicina)
Vicente Gómez, José Ángel (Universitat Pompeu Fabra)
Hernández Guillamet, Guillem (Institut Germans Trias i Pujol)
Ricou Ríos, Laura (Institut Germans Trias i Pujol)
Carrete, Andrea (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Vilalta, Victoria (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Estrada Cuxart, Oriol (Institut Germans Trias i Pujol)
Ara del Rey, Jordi (Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares)
Lupón, Josep (Institut Català de la Salut. Gerència Territorial Metropolitana Nord)
Bayés-Genís, Antoni (Institut Català de la Salut. Gerència Territorial Metropolitana Nord)
López Seguí, Francesc (Universitat de Vic)

Data:	2024
Resum:	Aims: The objective of this study was to perform a cost-benefit analysis of the CardioMEMS HF System (Abbott Laboratories, Abbott Park, IL, USA) in a heart failure (HF) clinic in Spain by evaluating the real-time remote monitoring of pulmonary artery pressures, which has been shown to reduce HF-related hospitalizations and improve the quality of life for selected HF patients. Particularly, the study aimed to determine the value of CardioMEMS in Southern Europe, where healthcare costs are significantly lower and its effectiveness remains uncertain. Methods and results: This single-centre study enrolled all consecutive HF patients (N = 43) who had been implanted with a pulmonary artery pressure sensor (CardioMEMS HF System); 48. 8% were females, aged 75. 5 ± 7. 0 years, with both reduced and preserved left ventricular ejection fraction; 67. 4% of them were in New York Heart Association Class III. The number of HF hospitalizations in the year before and the year after the sensor implantation was compared. Quality-adjusted life years gained based on a literature review of previous studies were calculated. The rate of HF hospitalizations was significantly lower at 1 year compared with the year before CardioMEMS implantation (0. 25 vs. 1. 10 events/patient-year, hazard ratio 0. 22, P = 0. 001). At the end of the first year, the usual management outperformed the CardioMEMS HF System. By the end of the second year, the CardioMEMS system is estimated to reduce costs compared with usual management (net benefits of €346). Conclusions: Based on the results, we suggest that remote monitoring of pulmonary artery pressure with the CardioMEMS HF System represents a midterm and long-term efficient strategy in a healthcare setting in Southern Europe.
Drets:	Aquest material està protegit per drets d'autor i/o drets afins. Podeu utilitzar aquest material en funció del que permet la legislació de drets d'autor i drets afins d'aplicació al vostre cas. Per a d'altres usos heu d'obtenir permís del(s) titular(s) de drets.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Heart failure ; Hospitalizations ; Monitoring ; Pulmonary pressure sensor ; Cost-benefit
Publicat a:	ESC Heart Failure, Vol. 11 Núm. 4 (august 2024) , p. 1955-1962, ISSN 2055-5822

DOI: 10.1002/ehf2.14698
PMID: 38500304

8 p, 300.5 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Articles de recerca
Articles > Articles publicats